+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North America Continuous Glucose Monitoring Device Market By Component, By End User, By Country, Industry Analysis and Forecast, 2020 - 2026

  • ID: 5026310
  • Report
  • April 2020
  • Region: North America
  • 76 Pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

FEATURED COMPANIES

  • Abbott Laboratories
  • DexCom, Inc.
  • Echo Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlySens, Incorporated
  • Johnson and Johnson
The North America Continuous Glucose Monitoring Device Market is expected to witness market growth of 11.6% CAGR during the forecast period (2020-2026).

Continuous glucose monitors (CGMs) contain subcutaneous sensors that track interstitial glucose levels every 1-5 minutes, offering alerts when glucose levels are too high or too low, or increase or fall rapidly. CGMs transmit to a receiver which is either a pager-like device or an insulin pump integral to it. Looking at the continuous glucose graph and the alarm response can help patients avoid severe hyperglycemia or hypoglycemia.

These systems, unlike conventional glucose monitors, allow for periodic monitoring of glucose levels, which is critically important for avoiding diabetic complications. In fact, GCMS research has set out a blueprint for the artificial/bionic pancreas that is much awaited, high-tech, closed-loop. Thus, the development of novel and technologically advanced CGMS is the primary focus of the manufacturing companies that monitor glucose devices. It offers a broad range of applications for all age cohorts, healthcare settings, and geographies. Thus, the market for continuous glucose monitoring devices provides lucrative opportunities for producers of CGMS and manufacturers of insulin pumps.

Several governments across the globe are introducing various diabetes treatment measures, allowing continuous glucose monitoring devices to be more widely adopted. Diabetes challenges the US population's health in many ways. The high prevalence and cost of diabetes are two reasons that have enforced the US government to control diabetes more effectively. In order to better control diabetes, the government is implementing a variety of actions addressing lifestyle and socioeconomic factors, screening and medical management, and public awareness campaigns.

Based on Component, the market is segmented into Sensors, Transmitters, and Receivers. Based on End User, the market is segmented into Hospitals, Homecare Settings and Other End Users. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, DexCom, Inc., Ypsomed AG, Senseonics Holdings, Inc., GlySens, Incorporated, A. Menarini Diagnostics Ltd. (The Menarini Group), Echo Therapeutics, Inc., Johnson and Johnson

Scope of the Study

Market Segmentation:

By Component
  • Sensors
  • Transmitters and
  • Receivers

By End User
  • Hospitals
  • Homecare Settings and
  • Other End Users

By Country
  • US
  • Canada
  • Mexico
  • Rest of North America

Companies Profiled:
  • Abbott Laboratories
  • Medtronic PLC
  • F. Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S
  • DexCom, Inc.
  • Ypsomed AG
  • Senseonics Holdings, Inc.
  • GlySens, Incorporated
  • A. Menarini Diagnostics Ltd. (The Menarini Group)
  • Echo Therapeutics, Inc.
  • Johnson and Johnson

Unique Offerings from the Publisher:
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • DexCom, Inc.
  • Echo Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlySens, Incorporated
  • Johnson and Johnson

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Continuous Glucose Monitoring Device Market, by Component
1.4.2 North America Continuous Glucose Monitoring Device Market, by End User
1.4.3 North America Continuous Glucose Monitoring Device Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Continuous Glucose Monitoring Device Market by Component
3.1 North America Sensors Market by Country
3.2 North America Transmitters Market by Country
3.3 North America Receivers Market by Country
Chapter 4. North America Continuous Glucose Monitoring Device Market by End-user
4.1 North America Hospitals Continuous Glucose Monitoring Device Market by Country
4.2 North America Homecare Settings Market by Country
4.3 North America Other End Users Market by Country
Chapter 5. North America Continuous Glucose Monitoring Device Market by Country
5.1 US Continuous Glucose Monitoring Device Market
5.1.1 US Continuous Glucose Monitoring Device Market by Component
5.1.2 US Continuous Glucose Monitoring Device Market by End-user
5.2 Canada Continuous Glucose Monitoring Device Market
5.2.1 Canada Continuous Glucose Monitoring Device Market by Component
5.2.2 Canada Continuous Glucose Monitoring Device Market by End-user
5.3 Mexico Continuous Glucose Monitoring Device Market
5.3.1 Mexico Continuous Glucose Monitoring Device Market by Component
5.3.2 Mexico Continuous Glucose Monitoring Device Market by End-user
5.4 Rest of North America Continuous Glucose Monitoring Device Market
5.4.1 Rest of North America Continuous Glucose Monitoring Device Market by Component
5.4.2 Rest of North America Continuous Glucose Monitoring Device Market by End-user
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Product Launches and Product Expansions:
6.2 Medtronic PLC
6.2.1 Company overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expenses
6.2.5 Recent strategies and developments:
6.2.5.1 Partnerships, Collaborations, and Agreements:
6.2.5.2 Acquisition and Mergers:
6.2.5.3 Approvals:
6.3 F. Hoffmann-La Roche Ltd.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.3.5.2 Acquisition and Mergers:
6.4 Novo Nordisk A/S
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental & Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Acquisition and Mergers:
6.5 DexCom, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Partnerships, Collaborations, and Agreements:
6.5.5.2 Approvals:
6.6 Ypsomed AG
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 Senseonics Holdings, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Partnerships, Collaborations, and Agreements:
6.7.5.2 Approvals:
6.8 GlySens, Incorporated
6.8.1 Company Overview
6.8.2 Recent strategies and developments:
6.8.2.1 Approvals:
6.9 A. Menarini Diagnostics Ltd. (The Menarini Group)
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Partnerships, Collaborations, and Agreements:
6.1 Echo Therapeutics, Inc.
6.10.1 Company Overview
6.11 Johnson and Johnson
6.11.1 Company Overview
6.11.2 Financial Analysis
6.11.3 Segmental &Regional Analysis
6.11.4 Research & Development Expenses
6.11.5 Recent strategies and developments:
6.11.5.1 Approvals:
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Medtronic PLC
  • F. Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S
  • DexCom, Inc.
  • Ypsomed AG
  • Senseonics Holdings, Inc.
  • GlySens, Incorporated
  • A. Menarini Diagnostics Ltd. (The Menarini Group)
  • Echo Therapeutics, Inc.
  • Johnson and Johnson
Note: Product cover images may vary from those shown

Loading
LOADING...